Literature DB >> 9534982

Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro.

A Gruber1, E Lukasser-Vogl, M Borg-von Zepelin, M P Dierich, R Würzner.   

Abstract

Previously, it has been shown that human immunodeficiency virus (HIV)-1 envelope proteins gp160 and gp41 bind to Candida albicans. Whether this interaction affects candidal virulence in vitro was investigated. HIV-1 gp160 or gp120 treatment of C. albicans significantly altered neither growth nor phospholipase activity of the fungus. However, treatment of C. albicans with gp160, but not with gp120, led to an elevation of free and cell-bound aspartate proteinase. In addition, culture supernatants obtained from C. albicans treated with gp160 or gp41, but not with gp120, showed a strong increase in proteinase activity. Finally, C. albicans viable yeast cells treated with gp160 or gp41 and serum were phagocytosed by polymorphonuclear leukocytes to a lesser extent than was C. albicans treated with gp120 and serum or serum alone. These findings suggest that the interaction between HIV-1 gp160 and C. albicans may promote the virulence of C. albicans in HIV-1-positive patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9534982     DOI: 10.1086/515231

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Lack of ritonavir antifungal effect in vitro.

Authors:  P Diz; A Ocampo; I Iglesias; I Otero
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women.

Authors:  F de Bernardis; F Mondello; G Scaravelli; A Pachì; A Girolamo; L Agatensi; A Cassone
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2010-02-26

4.  Candida albicans Hgt1p, a multifunctional evasion molecule: complement inhibitor, CR3 analogue, and human immunodeficiency virus-binding molecule.

Authors:  Iwona Lesiak-Markowicz; Georgia Vogl; Tobias Schwarzmüller; Cornelia Speth; Cornelia Lass-Flörl; Manfred P Dierich; Karl Kuchler; Reinhard Würzner
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

5.  Impact of N-chlorotaurine on viability and production of secreted aspartyl proteinases of Candida spp.

Authors:  Markus Nagl; Andreas Gruber; Anita Fuchs; Claudia P Lell; Eva-Maria Lemberger; Margarete Borg-Von Zepelin; Reinhard Würzner
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro.

Authors:  A Gruber; C P Lell; C Speth; H Stoiber; C Lass-Flörl; A Sonneborn; J F Ernst; M P Dierich; R Würzner
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 7.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  Candida albicans secreted aspartyl proteinases in virulence and pathogenesis.

Authors:  Julian R Naglik; Stephen J Challacombe; Bernhard Hube
Journal:  Microbiol Mol Biol Rev       Date:  2003-09       Impact factor: 11.056

9.  Basidiomycete metabolites attenuate virulence properties of Candida albicans in vitro.

Authors:  Barbara Falkensammer; Lisa Pleyer; Sigrun Ressler; Albrecht Berg; Margarethe Borg-von Zepelin; Markus Nagl; Cornelia Lass-Flörl; Cornelia Speth; Manfred P Dierich; Reinhard Würzner
Journal:  Mycoses       Date:  2008-04-16       Impact factor: 4.377

10.  Immune evasion by acquisition of complement inhibitors: the mould Aspergillus binds both factor H and C4b binding protein.

Authors:  G Vogl; I Lesiak; D B Jensen; S Perkhofer; R Eck; C Speth; C Lass-Flörl; P F Zipfel; A M Blom; M P Dierich; R Würzner
Journal:  Mol Immunol       Date:  2007-10-25       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.